Fresenius SE launches biosimilar of Roche’s Actemra

Fresenius SE (FSNUY), via its operating company Fresenius Kabi, announced the immediate U.S. availability of Tyenne, a biosimilar of Roche’s (RHHBY) Actemra. Tyenne, for use in the treatment of chronic autoimmune diseases, is available in an intravenous formulation. The company said, “Overall, we have seen an excellent performance of our (Bio)Pharma business in 2024 so far. We are particularly happy with the good progress of our majority-owned biotechnology company mAbxience and the traction of Tyenne, the first tocilizumab biosimilar available in Europe since November 2023.”